Sarthak Metals is a Value Buy

Our new Investor Relations client Sarthak Metals offers great value to investors at the current price. Firstly, its business: Sarthak Metals is a supplier of couple of important ingredients in the manufacture of steel. While the name may suggest that Sarthak is a manufacturer of metals, it is a supplier…

Read More

CL Educate rounds off a good FY22

FY22 saw CL Educate once again moving ahead purposefully. Several positives emerged: Reported EBITDA had a healthy look, growth returned, surplus real estate was partly disposed, debt reduced and net cash increased, merger of subsidiaries got consummated. The management is now firmly focused on pursuing growth objectives in both EdTech…

Read More

Sharp drop in Global Biotech VC investments

2022 is witnessing a sharp drop in global biotech investments by venture capital funds. Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%.   While the drop…

Read More

Chemcrux is planning a bigger future now

The first half of FY22 has seen some significant steps taken by the Chemcrux management, that signify a more aggressive intent towards the future growth of the company. Financial performance of FY22H1 has been good as well, with net profit increasing 16% over FY21H1, which was impacted by Covid.  The…

Read More

CL’s Career Launcher targeting 7x network expansion in 3 years

We have written earlier that Edtech and Martech player CL Educate is a stock in a positive upcycle. FY22 has already seen a chain of positive developments. CL’s newsletter for its Test Prep business for Nov’21 shows the rapid pace of developments at the company. Some key snippets: CL is…

Read More

CL Educate Q2: Recovery picks up speed

After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…

Read More

USD 3.3B of VC/PE investment in lifesciences firms in Sep’21

We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…

Read More

Sales Multiple Biryani or PE Biryani

The other day I was talking to a person who is an early-stage investor. He was looking to invest in a food business. He explained to me his criterion: he said his fund wanted to invest in a sales-multiple food business. This foxed me. I have heard of packaged food…

Read More

CL Educate heads into a positive cycle

After 2 years – FY20 and FY21 – of hanging tough, CL Educate appears to have entered a cycle of positive developments from FY22. Q1 FY22 results showed early indications of this. Firstly, there are signs of return to growth, despite Covid-2 wave still going strong in Q1 FY22. Stand…

Read More

USD 6.5B of VC/PE investment in lifesciences firms in June’21

We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…

Read More